Exelixis Stock Gains Institutional Confidence in Q3 2026

Exelixis, Inc. (NASDAQ: EXEL) has seen a surge in institutional investor interest in the third quarter of 2026, with CreativeOne Wealth LLC significantly boosting its stake. This move, along with strategic investments from other major players, highlights growing confidence in the biotechnology company’s future. Let’s break down the key developments and what they mean for Exelixis stock.

Institutional Investors Boost Exelixis Holdings

CreativeOne Wealth LLC increased its position in Exelixis by 135.9% during Q3 2026, acquiring an additional 18,495 shares to hold 32,102 shares total. This stake is valued at $1.326 million, reflecting strong institutional backing. Other notable investors, including Grantham Mayo Van Otterloo and Teton Advisors, also added to their positions, with combined institutional ownership now at 85.27% of the company’s stock.

Key Institutional Moves

• Grantham Mayo Van Otterloo: New position worth $489,000.
• Neo Ivy Capital Management: Raised stake by 12.8% to 14,466 shares ($597,000).
• Neuberger Berman Group: Increased holdings by 9.1% to 34,264 shares ($1.415 million).

Exelixis Stock Performance and Analyst Outlook

As of March 11, 2026, Exelixis stock opened at $41.29, down 2.5% from recent levels. The stock trades with a 52-week range of $32.38 to $49.62 and a market cap of $10.72 billion. Analysts remain cautiously optimistic, with a consensus “Hold” rating and an average price target of $46.94. Recent earnings reports showed improved performance, with Q4 2025 EPS of $0.94, exceeding estimates by $0.20.

Analyst Price Targets

• UBS Group: $41.00 target price.
• Stifel Nicolaus: Raised target to $44.00 with a “Hold” rating.
• Truist Financial: $51.00 target price.

Insider Transactions and Corporate Confidence

Insiders have also been active in the stock. Director Bob Oliver sold 30,250 shares for $1.325 million, reducing his stake by 58.89%. EVP Patrick J. Haley sold 67,814 shares, trimming his holdings by 15.08%. While these sales may raise questions, the broader institutional trend suggests continued confidence in Exelixis’ long-term potential.

Why Institutional Confidence Matters

Institutional investors often act as barometers for market sentiment. Their increased stakes in Exelixis signal belief in the company’s pipeline, particularly its focus on kinase inhibitors for cancer treatment. With products like CABOMETYX® and COMETRIQ® driving revenue growth, Exelixis remains a key player in oncology innovation.

Conclusion: Is Exelixis Stock a Buy?

Exelixis stock has shown resilience despite short-term volatility. While insider sales may warrant caution, the broader institutional trend and analyst ratings suggest a balanced outlook. Investors should monitor upcoming earnings reports and clinical trial updates for further guidance. For now, Exelixis appears well-positioned to capitalize on its biotech expertise.

FAQs

What is the current price of Exelixis stock?

As of March 11, 2026, Exelixis stock opened at $41.29.

Why are institutional investors buying Exelixis stock?

Institutional confidence stems from Exelixis’ strong pipeline and revenue growth, with 85.27% of shares held by institutions.

What is the analyst consensus for EXEL?

Analysts rate Exelixis with a “Hold” consensus and an average price target of $46.94.

How has Exelixis performed in recent quarters?

Exelixis reported Q4 2025 EPS of $0.94, exceeding estimates, and revenue of $598.66 million.

Should I consider buying Exelixis stock?

Investors should evaluate their risk tolerance and consult financial advisors before making decisions.